Ximelagatran for prevention and treatment of venous thromboembolism

Kwok L
Record ID 32004000641
English, French
Authors' objectives:

To summarize the available information on the use of ximelagatran (Trade Name Exanta, manufactured by AstraZeneca)in the prevention of venous thromboembolism after major orthopedic surgery. Ximelagatran is the first oral agent in a new class of anticoagulants called 'direct thrombin inhibitors'.

Authors' recomendations: Most of the available evidence regarding venous thromboembolism (VTE) is from studies focusing on its prevention after major orthopedic surgery. Ximelagatran's efficacy is comparable to that of warfarin and low-molecular-weight heparin in this setting. The rates of bleeding complications for this drug and its comparators were not statistically different. The elevation of liver enzymes was observed in longer term trials. Given its simplicity of use, ximelagatran may replace, at least partly, the anticoagulants used in the management of VTE. It use beyond VTE prevention and treatment may be anticipated, given that it has been evaluated in stroke prevention and cardiac trials.
Authors' methods: Overview
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 2004
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Anticoagulants
  • Orthopedics
  • Thromboembolism
  • Venous Thrombosis
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.